Scienza e Tecnologia
SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field
Liver cancer is the fourth most common type of cancer in the world (Huang DQ , 18, 223-238, 2021). The proportion of MASH/NASH patterns with non-virus-related cancer is also increasing annually. In addition to molecular target drugs such as and , immune checkpoint inhibitors (ICIs) such as , , and have also recently been used in clinical practice as therapeutic drugs for liver cancer. Therefore, future developments are highly anticipated. (Chen C , 14, 1133308, 2023). However, the response rate of ICIs for liver cancer is still low, ranging from 0-14%, compared to other types of cancer (e.g., melanoma response rate; 35-70%), thus there is a great demand for the development of new treatments (Tan S , 4, 579-597, 2022, Valero C , 7, 1245-1246, 2021). Due to this information, along with recent revelations in the field of tumor immunology, SMC Laboratories has successfully leveraged the characteristics of its STAM™-HCC/IO mouse, which enables the provision of non-clinical pharmacological services for new liver cancer therapeutics, including ICIs.
Through the company's research, it has become apparent that the STAM™-HCC/IO mouse model has a high tumor mutation burden with the following features:
These characteristics are extremely useful in evaluating treatments based on tumor immune control in non-clinical studies, and the STAM™-HCC/IO mouse, which has all of these features, is currently the most suitable non-clinical liver cancer mouse model for tumor immunology research (Shalapour S , 340-345, 2017, Dow M : E9879-E9888, 2018). It is possible to evaluate the anti-tumor effects of ICIs not only in monotherapy studies but also in combination studies. This can be accomplished by using anti-PD-L1 antibody as a control, and directly comparing results.
SMC Laboratories, Inc. is a CRO, with a focus on conducting the non-clinical research necessary for the drug development process. As a global consulting company that designs studies according to customer requests, it supports cutting-edge non-clinical pharmacological studies. The company owns a variety of mouse models for inflammation and fibrosis in various organs, centered on the innovative STAM™ mouse' animal model of liver cancer derived from MASLD (metabolic dysfunction-associated steatotic liver disease). This patented mouse model was developed by SMC Laboratories as a worldwide-first model based on MASLD. We offer non-clinical pharmacological studies using the model mouse. Please check the company's website for further details.
For further inquiries, please visit SMC Laboratories Inc., SMC Laboratories (smccro-lab.com) or contact Taishi Hashiguchi , Ph.D. by t.hashiguchi@smccro-lab.com or info@smccro-lab.com .
Media Contact: Miyu Ueno m.ueno@smccro-lab.com
View original content:https://www.prnewswire.co.uk/news-releases/smc-laboratories-reveals-innovative-stam-hccio-mouse-for-identifying-and-developing-novel-therapeutic-drugs-for-liver-cancer-blazing-a-trail-in-the-immuno-oncology-field-302054039.html